Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles

Massimo Bonora; Mariusz R. Wieckowski; David A. Sinclair; Guido Kroemer; Paolo Pinton; Lorenzo Galluzzi

doi:10.1038/s41569-018-0074-0

Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles

Massimo Bonora
, Mariusz R. Wieckowski
, David A. Sinclair
, Guido Kroemer
, Paolo Pinton
, Lorenzo Galluzzi

Albert Einstein College of Medicine
Nencki Institute of Experimental Biology of the Polish Academy of Sciences
Harvard University
University of New South Wales
Centre de Recherche des Cordeliers
Institut national de la santé et de la recherche médicale
Université Paris Cité
Sorbonne Université
Université Paris-Sud
Assistance publique – Hôpitaux de Paris
Karolinska Institutet
University of Ferrara
Maria Cecilia Hospital
Cornell University

Research output: Contribution to journal › Review article › peer-review

275 Scopus citations

Abstract

A large body of evidence indicates that mitochondrial dysfunction has a major role in the pathogenesis of multiple cardiovascular disorders. Over the past 2 decades, extraordinary efforts have been focused on the development of agents that specifically target mitochondria for the treatment of cardiovascular disease. Despite such an intensive wave of investigation, no drugs specifically conceived to modulate mitochondrial functions are currently available for the clinical management of cardiovascular disease. In this Review, we discuss the therapeutic potential of targeting mitochondria in patients with cardiovascular disease, examine the obstacles that have restrained the development of mitochondria-targeting agents thus far, and identify strategies that might empower the full clinical potential of this approach.

Original language	English
Pages (from-to)	33-55
Number of pages	23
Journal	Nature Reviews Cardiology
Volume	16
Issue number	1
DOIs	https://doi.org/10.1038/s41569-018-0074-0
State	Published - Jan 1 2019
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41569-018-0074-0

Cite this

@article{9703fc22e71b46faa8928ee8e6d77470,

title = "Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles",

abstract = "A large body of evidence indicates that mitochondrial dysfunction has a major role in the pathogenesis of multiple cardiovascular disorders. Over the past 2 decades, extraordinary efforts have been focused on the development of agents that specifically target mitochondria for the treatment of cardiovascular disease. Despite such an intensive wave of investigation, no drugs specifically conceived to modulate mitochondrial functions are currently available for the clinical management of cardiovascular disease. In this Review, we discuss the therapeutic potential of targeting mitochondria in patients with cardiovascular disease, examine the obstacles that have restrained the development of mitochondria-targeting agents thus far, and identify strategies that might empower the full clinical potential of this approach.",

author = "Massimo Bonora and Wieckowski, \{Mariusz R.\} and Sinclair, \{David A.\} and Guido Kroemer and Paolo Pinton and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2018, Springer Nature Limited.",

year = "2019",

month = jan,

day = "1",

doi = "10.1038/s41569-018-0074-0",

language = "English",

volume = "16",

pages = "33--55",

journal = "Nature Reviews Cardiology",

issn = "1759-5002",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Targeting mitochondria for cardiovascular disorders

T2 - therapeutic potential and obstacles

AU - Bonora, Massimo

AU - Wieckowski, Mariusz R.

AU - Sinclair, David A.

AU - Kroemer, Guido

AU - Pinton, Paolo

AU - Galluzzi, Lorenzo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - A large body of evidence indicates that mitochondrial dysfunction has a major role in the pathogenesis of multiple cardiovascular disorders. Over the past 2 decades, extraordinary efforts have been focused on the development of agents that specifically target mitochondria for the treatment of cardiovascular disease. Despite such an intensive wave of investigation, no drugs specifically conceived to modulate mitochondrial functions are currently available for the clinical management of cardiovascular disease. In this Review, we discuss the therapeutic potential of targeting mitochondria in patients with cardiovascular disease, examine the obstacles that have restrained the development of mitochondria-targeting agents thus far, and identify strategies that might empower the full clinical potential of this approach.

AB - A large body of evidence indicates that mitochondrial dysfunction has a major role in the pathogenesis of multiple cardiovascular disorders. Over the past 2 decades, extraordinary efforts have been focused on the development of agents that specifically target mitochondria for the treatment of cardiovascular disease. Despite such an intensive wave of investigation, no drugs specifically conceived to modulate mitochondrial functions are currently available for the clinical management of cardiovascular disease. In this Review, we discuss the therapeutic potential of targeting mitochondria in patients with cardiovascular disease, examine the obstacles that have restrained the development of mitochondria-targeting agents thus far, and identify strategies that might empower the full clinical potential of this approach.

UR - https://www.scopus.com/pages/publications/85053041945

U2 - 10.1038/s41569-018-0074-0

DO - 10.1038/s41569-018-0074-0

M3 - Review article

C2 - 30177752

AN - SCOPUS:85053041945

SN - 1759-5002

VL - 16

SP - 33

EP - 55

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

IS - 1

ER -

Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this